-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
MSD avbryter två cancerprojekt efter misslyckade studier
Merck & Co, eller MSD som det heter i Europa, avbryter fas 3-studierna för två läkemedelsprogram för olika former av cancer efter misslyckanden i studier.
-
Investigations against AstraZeneca: ”Chinese interests may be behind them”
Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.
-
AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
-
BioArctic moves forward with its candidate for Parkinson’s
BioArctic announces positive early phase study results for its drug candidate for Parkinson’s disease.
-
MSD discontinues two Keytruda trials
MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.
-
MSD lägger ned två Keytruda-studier
Amerikanska MSD har avbrutit två studier i sen fas där bolagets storsäljande immunterapi Keytruda prövats som behandling mot hud- respektive lungcancer.